Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

Treatment satisfaction with calcitonin gene‐related peptide monoclonal antibodies as a new patient‐reported outcome measure: A real‐life experience in migraine

(2022) Alba López‐Bravo et al.   ACTA NEUROLOGICA SCANDINAVICA

Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients

(2022) Soonwook Kwon et al.   CEPHALALGIA

A long-term open-label safety study of galcanezumab in Japanese patients with migraine

(2021) Koichi Hirata et al.   Expert Opinion On Drug Safety

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

(2021) Michael Ament et al.   JOURNAL OF HEADACHE AND PAIN

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

(2021) Fabrizio Vernieri et al.   JOURNAL OF HEADACHE AND PAIN

The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study

(2021) Marta Torres-Ferrús et al.   JOURNAL OF NEUROLOGY

Inflammatory complications of CGRP monoclonal antibodies: a case series

(2021) Jason C. Ray et al.   JOURNAL OF HEADACHE AND PAIN

Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study

(2020) Ashley Alex et al.   HEADACHE

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

(2020) Wim M Mulleners et al.   LANCET NEUROLOGY

Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)

(2020) Fabrizio Vernieri et al.   NEUROLOGICAL SCIENCES

Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019

(2020) T. J. Steiner et al.   JOURNAL OF HEADACHE AND PAIN

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Russell Nichols et al.   JOURNAL OF HEADACHE AND PAIN

Discovery of CGRP in relation to migraine

(2019) Lars Edvinsson et al.   CEPHALALGIA

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care

(2018) Kumiko Muramatsu et al.   GENERAL HOSPITAL PSYCHIATRY

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment

(2018) Stephen D. Silberstein et al.   HEADACHE

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

(2018)   HEADACHE

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY